NCT02458235View on ClinicalTrials.gov

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 2, 2015

Primary Completion Date

March 15, 2019

Study Completion Date

March 15, 2019

Conditions
Acute Myelogenous LeukemiaAcute Lymphoid LeukemiaJuvenile Myelomonocytic LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

azacitidine

40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals

BIOLOGICAL

donor lymphocyte infusion

For patients with cells available for DLI who are in the high risk group and do not have graft-versus-host disease (GVHD), DLI will be adminstered on day 5 of each cycle.

Trial Locations (1)

94143

University of California San Francisco, San Francisco

Sponsors

Collaborators (1)

Hellman Foundation
All Listed Sponsors
collaborator

Hellman Foundation

OTHER

lead

University of California, San Francisco

OTHER